Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043872 · ClinicalTrials.gov registry record · Phase 3
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
A Phase 3 study of Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 987
- Enrollment target
- 20
- Study locations
NCT03043872: Active Phase 3 study of Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca.
NCT03043872 is a Phase 3 study of Small Cell Lung Carcinoma Extensive Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 987 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03043872, a Phase 3 study of Small Cell Lung Carcinoma Extensive Disease, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 987 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Primary Outcome
OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An interim analysis of OS in the global cohort was pre-specified after approximately 318 OS events occurred each between the D + EP and EP groups (60% maturity), and between the D + T + EP and EP groups (60% m
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Indiana
- Research Site - Fort Wayne
- Research Site - Muncie
Kansas
- Research Site - Leawood
- Research Site - Wichita
Ohio
- Research Site - Cleveland
- Research Site - Columbus
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Scottsdale
Arkansas
- Research Site - Rogers
California
- Research Site - Santa Monica
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 987 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
What the registry record for NCT03043872 still lists
NCT03043872 is an interventional study that assigns participants to a tested intervention. The registered 987 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Small Cell Lung Carcinoma Extensive Disease appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03043872 names 20 study sites across 17 states, led by Indiana, Kansas, Ohio.
Frequently Asked Questions
What is clinical trial NCT03043872 about?
NCT03043872 is a clinical study titled "Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)". This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with ...
What is the current status of trial NCT03043872?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 987 participants. The study started on 2017-03-27. Estimated completion is 2025-12-31.
What conditions does trial NCT03043872 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma Extensive Disease.
What interventions are being tested in trial NCT03043872?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03043872?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03043872 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03043872's enrollment target sits among peer trials
987 320th of 2000 higher than 1,681 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI